TORONTO, May 6, 2014 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation") today announced that at the annual and special meeting (the "Meeting") of shareholders of the Corporation ("Shareholders") that was held yesterday, all six nominees for the board were elected,
the voting results of which are as follows:
|
Director
|
Number and percentage of
shares represented in person or
by proxy and entitled to vote at
the Meeting that voted FOR
|
Number and percentage of
shares represented in person or
by proxy and entitled to vote at
the Meeting that were
WITHHELD from voting
|
|
Anthony Bihl III
|
74,241,553 (99.55%)
|
339,181 (0.45%)
|
|
Kevin Giese
|
71,632,600 (96.05%)
|
2,948,134 (3.95%)
|
|
Guillermo Herrera
|
74,084,173 (99.33%)
|
496,561 (0.67%)
|
|
Paul M. Walker
|
74,141,164 (99.41%)
|
439,570 (0.59%)
|
|
Laine Woollard
|
74,094,776 (99.35%)
|
485,958 (0.65%)
|
|
Koichiro Takeshita
|
74,254,387 (99.56%)
|
326,347 (0.44%)
|
At the Meeting, Shareholder also approved the name change of the
Corporation to "Spectral Medical Inc." but that name change will only
take effect if, as and when adopted by the board of directors of the
Corporation at a later date. Lastly, Shareholders also approved the
amendments to the terms of those certain warrants of the Corporation
held by insiders to extend the expiry date of the warrants from March
2, 2014 to September 2, 2014, consistent with the amendments made to
the warrants held by all other holders of warrants.
Full details of the foregoing are contained in the Report of Voting
Results for the Meeting which has been filed on Sedar at www.Sedar.com.
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead
theranostics product for the treatment of severe sepsis with septic
shock. PMX is a therapeutic hemoperfusion device that removes
endotoxin, which can cause sepsis, from the bloodstream. Directed by
the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared
diagnostic for the risk of developing sepsis. Spectral's EUPHRATES
trial is the world's only active and most innovative Phase III study in
the area of septic shock.
PMX has been approved for therapeutic use in Japan and Europe, and has
been used safely and effectively on more than 100,000 patients to date.
In March 2009, Spectral obtained the exclusive development and
commercial rights in the U.S. for PMX, and in November 2010, signed an
exclusive distribution agreement for this product in Canada.
Approximately 350,000 patients are diagnosed with severe sepsis and
septic shock in North America each year, representing a greater than $1
billion market opportunity for Spectral. Spectral is listed on the
Toronto Stock Exchange under the symbol
Forward-looking statement
Information in this news release that is not current or historical
factual information may constitute forward looking information within
the meaning of securities laws. Implicit in this information,
particularly in respect of the future outlook of Spectral and
anticipated events or results, are assumptions based on beliefs of
Spectral's senior management as well as information currently available
to it. While these assumptions were considered reasonable by Spectral
at the time of preparation, they may prove to be incorrect. Readers are
cautioned that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business
opportunities in the biomedical industry, the granting of necessary
approvals by regulatory authorities as well as general economic, market
and business conditions, and could differ materially from what is
currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
SOURCE Spectral Diagnostics Inc.
